Evidence map›Paper›PMID 34923645›Full record

ReviewImmunological reviews2022

ZAP70, too little, too much can lead to autoimmunity.

Judith F Ashouri, Wan-Lin Lo, Trang T T Nguyen, Lin Shen, Arthur Weiss

Open access · hybridAbstract readReview
In one paragraph

Review in Immunological reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frontiers in immunology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Judith F AshouriDepartment of Medicine, Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, California, USA.
Wan-Lin LoDivision of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, Utah, USA.ORCID 0000-0002-9074-6847
Trang T T NguyenDepartment of Medicine, Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, California, USA.
Lin ShenDepartment of Medicine, Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, California, USA.
Arthur WeissDepartment of Medicine, Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-2414-9024
University of California, San Francisco · USHoward Hughes Medical Institute · USUniversity of Utah · US

Funding

Understand the metabolic fitness of naïve T cellsP01AI091580 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEROEN ROOSE · 2011 to 2026
$31.1M
The cell and molecular mechanisms underlying CD28 costimulationR37AI114575 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, ARTHUR · 2016 to 2023
$3.2M
Signaling and repertoire differences in arthritogenic T cellsK08AR072144 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ASHOURI, JUDITH · 2018 to 2022
$887k
Regulation of T cell ligand discrimination by tuning the phosphorylation kinetics of Zap70 substratesK22AI143960 · NIAID · UNIVERSITY OF UTAH · PI LO, WAN-LIN · 2021 to 2022
$270k
Howard Hughes Medical InstituteNIAID NIH HHS K22 AI143960NIAID NIH HHS P01 AI091580NIAID NIH HHS R37 AI114575NIAMS NIH HHS K08 AR072144NIAMS NIH HHS L30 AR066960
6 · The paper itself

Abstract

Establishing both central and peripheral tolerance requires the appropriate TCR signaling strength to discriminate self- from agonist-peptide bound to self MHC molecules. ZAP70, a cytoplasmic tyrosine kinase, directly interacts with the TCR complex and plays a central and requisite role in TCR signaling in both thymocytes and peripheral T cells. By studying ZAP70 hypomorphic mutations in mice and humans with a spectrum of hypoactive or hyperactive activities, we have gained insights into mechanisms of central and peripheral tolerance. Interestingly, both hypoactive and hyperactive ZAP70 can lead to the development of autoimmune diseases, albeit through distinct mechanisms. Immature thymocytes and mature T cells rely on normal ZAP70 function to complete their development in the thymus and to modulate T cell responses in the periphery. Hypoactive ZAP70 function compromises key developmental checkpoints required to establish central tolerance, allowing thymocytes with potentially self-reactive TCRs a greater chance to escape negative selection. Such 'forbidden clones' may escape into the periphery and may pose a greater risk for autoimmune disease development since they may not engage negative regulatory mechanisms as effectively. Hyperactive ZAP70 enhances thymic negative selection but some thymocytes will, nonetheless, escape negative selection and have greater sensitivity to weak and self-ligands. Such cells must be controlled by mechanisms involved in anergy, expansion of Tregs, and upregulation of inhibitory receptors or signaling molecules. However, such potentially autoreactive cells may still be able to escape control by peripheral negative regulatory constraints. Consistent with findings in Zap70 mutants, the signaling defects in at least one ZAP70 substrate, LAT, can also lead to autoimmune disease. By dissecting the similarities and differences among mouse models of patient disease or mutations in ZAP70 that affect TCR signaling strength, we have gained insights into how perturbed ZAP70 function can lead to autoimmunity. Because of our work and that of others on ZAP70, it is likely that perturbations in other molecules affecting TCR signaling strength will be identified that also overcome tolerance mechanisms and cause autoimmunity. Delineating these molecular pathways could lead to the development of much needed new therapeutic targets in these complex diseases.

Indexed as

Autoimmune DiseasesAutoimmunityAnimalsHumansImmune ToleranceMiceProtein-Tyrosine KinasesReceptors, Antigen, T-CellThymocytesThymus GlandProtein-Tyrosine KinasesReceptors, Antigen, T-CellautoimmunityLATTCR signalingtolerance and anergyZAP70

Identifiers

PMID34923645
PMCPMC8986586
OpenAlexW4200568616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.